|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0005682,
umls-concept:C0007138,
umls-concept:C0017262,
umls-concept:C0034802,
umls-concept:C0069515,
umls-concept:C0079419,
umls-concept:C0086418,
umls-concept:C0185117,
umls-concept:C0596988,
umls-concept:C1704824,
umls-concept:C2911684
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
1991-8-21
|
|
pubmed:abstractText |
Expression of the p53, the epidermal growth factor receptor (EGFr; c-erbB-1) and c-erbB-2 proteins was studied in 82 patients with primary transitional cell carcinoma of the bladder using an immuno-histochemical method. Strong or moderate staining was found in 18% of tumours for p53 with weaker staining in a further 36% giving a total of 54% of tumours stained for p53. Strong staining was found in 15% of tumours for c-erbB-2 and in 31% for the EGFr. Tumours invading the bladder muscle were significantly more likely to be strongly stained positively for p53 and/or EGFr compared with superficial tumours: only 15% of invasive tumours were stained negatively for both p53 and EGFr. No statistical association was found between p53 and EGFr expression. Weakly positive associations were found between the expression of c-erbB-2 and p53 and between muscle invasive tumours and increased expression of c-erbB-2. Alterations in the expression of p53, c-erbB-1 and c-erbB-2 were found frequently in human transitional cell carcinoma of the urinary bladder and may be of clinical use in defining patient sub-groups of differing prognosis.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/1712624-1691710,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1712624-1694291,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1712624-1699228,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1712624-1969059,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1712624-1978784,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1712624-2165234,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1712624-218111,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1712624-2293558,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1712624-2311071,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1712624-2370306,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1712624-2470152,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1712624-2476668,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1712624-2511965,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1712624-2525423,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1712624-2531845,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1712624-2554494,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1712624-2564806,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1712624-2642977,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1712624-2649981,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1712624-2821401,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1712624-2841597,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1712624-2857420,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1712624-2884496,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1712624-2885574,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1712624-2892196,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1712624-2904522,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1712624-2926561,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1712624-3005871,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1712624-3054153,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1712624-3276632,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1712624-3309672,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1712624-6390217
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
0007-0920
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
63
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
967-70
|
|
pubmed:dateRevised |
2009-11-19
|
|
pubmed:meshHeading |
pubmed-meshheading:1712624-Aged,
pubmed-meshheading:1712624-Carcinoma, Transitional Cell,
pubmed-meshheading:1712624-Female,
pubmed-meshheading:1712624-Gene Expression,
pubmed-meshheading:1712624-Humans,
pubmed-meshheading:1712624-Male,
pubmed-meshheading:1712624-Mutation,
pubmed-meshheading:1712624-Neoplasm Staging,
pubmed-meshheading:1712624-Proto-Oncogene Proteins,
pubmed-meshheading:1712624-Receptor, Epidermal Growth Factor,
pubmed-meshheading:1712624-Receptor, erbB-2,
pubmed-meshheading:1712624-Staining and Labeling,
pubmed-meshheading:1712624-Tumor Markers, Biological,
pubmed-meshheading:1712624-Tumor Suppressor Protein p53,
pubmed-meshheading:1712624-Urinary Bladder Neoplasms
|
|
pubmed:year |
1991
|
|
pubmed:articleTitle |
Expression of mutant p53, c-erbB-2 and the epidermal growth factor receptor in transitional cell carcinoma of the human urinary bladder.
|
|
pubmed:affiliation |
University Department of Pathology, Newcastle-upon-Tyne, UK.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
